Achilles Tendinopathy in NYC: Why PRP Outperforms Traditional Treatments
The Achilles tendon is the strongest and largest tendon in the human body — yet it is also one of the most injury-prone, particularly in active adults. Achilles tendinopathy affects runners, dancers, weekend athletes, and sedentary office workers alike. And while physical therapy provides the cornerstone of treatment, a significant subset of patients fail to achieve lasting relief through conservative measures alone. For these patients, regenerative orthopedics at RHPNY — specifically PRP injection therapy — offers a scientifically grounded path to tendon healing.
Understanding Achilles Tendinopathy
"Tendinopathy" is the current preferred term, having largely replaced "tendinitis" in the clinical literature. The shift reflects improved understanding of the pathology: chronic Achilles pain involves tendon degeneration, not primarily inflammation.
Histological studies of symptomatic Achilles tendons consistently show:
- Disorganized collagen fiber arrangement
- Neovascularization (abnormal blood vessel ingrowth)
- Increased water content (mucoid degeneration)
- Absence of significant inflammatory cell infiltration
This degenerative process — tendinosis — explains why anti-inflammatory treatments (NSAIDs, cortisone) provide incomplete and often temporary relief. The tendon needs rebuilding, not suppression of inflammation.
Two Forms of Achilles Tendinopathy
Mid-portion Achilles Tendinopathy
Pain and thickening in the tendon itself, approximately 2–6 cm above the heel bone. This is the most common form, associated with overuse and training load errors.
Insertional Achilles Tendinopathy
Pain at the junction of the tendon and heel bone (calcaneal insertion), often associated with Haglund's deformity (bony prominence on the heel). This form is mechanically distinct and somewhat more resistant to treatment.
The Limits of Conventional Treatment
Eccentric Loading Exercise
Eccentric (lengthening under load) exercises — particularly the Alfredson protocol of single-leg heel drops — are the gold standard conservative treatment. They promote collagen remodeling when performed correctly and consistently over 12+ weeks. Approximately 70–80% of mid-portion tendinopathy responds to eccentric loading.
But the responders require significant time, discipline, and often short-term symptom worsening before improvement. And 20–30% do not respond adequately.
Cortisone Injections
Cortisone is relatively contraindicated in Achilles tendinopathy — it provides temporary pain relief but weakens tendon collagen architecture and is associated with increased risk of tendon rupture, particularly in insertional tendinopathy.
Shockwave Therapy (ESWT)
Extracorporeal shock wave therapy stimulates a neovascularization response and shows efficacy in several RCTs. It is a reasonable option for patients who fail eccentric loading.
PRP for Achilles Tendinopathy: Evidence and Mechanism
Platelet-rich plasma delivers concentrated growth factors — PDGF, TGF-β, IGF-1, VEGF — directly into the degenerative tendon tissue. These signals:
- Stimulate tenocyte (tendon fibroblast) proliferation
- Promote organized type I collagen synthesis
- Improve local vascularity in a regulated way (unlike the pathological neovascularization of tendinosis)
- Down-regulate substance P signaling (pain mediator)
Clinical Evidence
A landmark randomized controlled trial published in JAMA (Gosens et al.) demonstrated that PRP injections for chronic Achilles tendinopathy produced superior VISA-A scores (validated outcome measure) compared to saline injections at 1 and 2 years follow-up. The treatment effect persisted and grew over time — consistent with ongoing tissue remodeling.
More recent systematic reviews confirm PRP as a clinically meaningful option for patients who have failed conservative care, particularly for mid-portion tendinopathy.
The RHPNY PRP Protocol for Achilles Tendinopathy
Dr. Ajit Dhaliwal performs Achilles PRP at RHPNY using ultrasound guidance for precise needle placement within the degenerative tendon zones.
Protocol:
- Diagnostic ultrasound assessment — quantifying tendon thickness, hypoechogenicity, and neovascularization pattern
- PRP preparation (15–20 mL blood draw, leukocyte-rich PRP formulation preferred for tendon)
- Ultrasound-guided injection — typically 1–2 injection points per session
- Post-injection loading protocol — controlled eccentric loading recommended 2 weeks post-injection to synergize with growth factor signaling
Most patients complete 2–3 injections over 6–8 weeks.
Realistic Expectations
- Weeks 1–2: Possible soreness — expected and represents healing response
- Weeks 4–8: Gradual pain reduction
- Months 3–6: Significant functional improvement
- 6–12 months: Tendon structural remodeling on follow-up ultrasound
Success rates for appropriately selected patients with chronic mid-portion Achilles tendinopathy are approximately 70–80% for meaningful pain reduction and return to activity.
Book a consultation at RHPNY if you have Achilles pain that has not resolved with conservative care. Our joint and orthopedic services include comprehensive tendon evaluation and personalized regenerative treatment planning.
---
This content is for educational purposes only and does not constitute medical advice. PRP therapy for Achilles tendinopathy at RHPNY is performed by Dr. Ajit Dhaliwal, MD, following a thorough clinical and ultrasound evaluation.
